Creation of PHAXIAM Therapeutics with effect from June 23, 2023, in order to form a world leader in phage therapy targeting high value-added indications
Development of an ambitious and value-creating clinical and regulatory strategy in the field of severe and resistant bacterial infections
o Launch of a first global pivotal phase 2b/3 study in osteoarticular prosthesis infections (PJI) planned for the second half of 2024
o Exchanges with the FDA (Pre-IND) and the EMA (scientific advice) planned for the 4th quarter of 2023 to finalize the design of the phase 2b/3 study in PJI
o Planning for the launch of the phase 1 study in endocarditis in the 4th quarter of 2023
Cash and cash equivalents amounting to €25.2 million ($27.5 million) as of June 30, 2023
Lyon (France) and Cambridge (MA, US), September 21, 10:05 p.m. CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today provides an update on its activities and presents its financial results for the first half of 2023.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]